2023 World Conference on Lung Cancer (Posters)-EP13.05. A Comparison of the Outcomes of Pulmonary versus Extrapulmonary Extensive Stage Small Cell Carcinoma

EP13.05. A Comparison of the Outcomes of Pulmonary versus Extrapulmonary Extensive Stage Small Cell Carcinoma - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to compare the outcomes of patients with extensive stage extrapulmonary small cell carcinoma (EPSCC) and small cell lung cancer (SCLC). The study, conducted at four Australian hospitals, included a total of 384 patients, with 43 having EPSCC and 340 having SCLC. <br /><br />The results showed that the overall median overall survival (OS) for EPSCC was 6.4 months, while for SCLC it was 7 months. Among those who received chemotherapy, the median OS for EPSCC was 10.4 months, compared to 8.4 months for SCLC. The median progression-free survival (PFS) was 5.4 months for EPSCC and 5.5 months for SCLC. The overall response rate (ORR) was 73% for EPSCC and 68% for SCLC.<br /><br />The study concluded that EPSCC and SCLC had comparable outcomes. However, the wide range of OS in EPSCC suggests the need for a better understanding of its genomics in order to explore alternative treatment options. <br /><br />The study highlights the importance of differentiating EPSCC from SCLC in terms of treatment strategies, as current approaches are often extrapolated from SCLC studies. The findings suggest that EPSCC may require tailored treatment options that take into consideration its unique characteristics. Further research is needed to enhance our understanding of EPSCC and develop more effective therapies.

Asset Subtitle

Emily Chen

Meta Tag

Speaker Emily Chen

Topic SCLC & Neuroendocrine Tumors: NETs

Keywords

study

outcomes

patients

EPSCC

SCLC

overall survival

chemotherapy

progression-free survival

treatment options

research